ReviewMolecular neurobiology2025
Genetic Manipulation in Organoid Models and Their Applications in Central Nervous System Pathologies.
Review in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently developed organoid technology represents a novel method of accurately mimicking in vivo conditions by simulating tissue architecture and intercellular interactions in 3 dimensions. Three-dimensional (3D) organoids can provide a more precise representation of in vivo drug action, as well as gene expression and cell differentiation, making them a valuable tool for testing newly developed drugs and simulating various pathologies of the central nervous system. By genetically modifying the cellular component of these organoids, one can induce differentiation into various cells of the human body, ranging from neurons to cells of the gastrointestinal tract, enabling the creation of 3D models of diverse organs of the human body. Here, we discuss various methods that can be used to induce genetic change in cells found in 3D media and possible applications of genetically modified organoids, such as their use in the simulation of pathologies of the central nervous system, and potential therapeutic application of optogenetics within these models. Clinical trial number: not applicable.
Indexed as
Identifiers
41264151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.